UBS Maintains Neutral on Moderna, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 65.8%

Neg 0% Neu 0% Pos 65.8%

UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $36 to $45.

Comments

No comments yet. Be the first!